Navigation Links
Prime Therapeutics Urges Caution on Mandates of Abuse-Deterrent Formulations of Opioids Citing Value Concerns
Date:7/20/2017

ST. PAUL, Minn., July 20, 2017 /PRNewswire/ -- Prime Therapeutics LLC (Prime) released this statement from its Chief Medical Officer, Jonathan Gavras, M.D., following today's Institute for Clinical and Economic Review's (ICER) public meeting reviewing its report on the effectiveness and value of abuse-deterrent formulations (ADF) of opioids. Prime was the sole pharmacy benefit manager on the policy roundtable at the meeting.

"The ICER data suggests there is not a material cost benefit to the use of abuse-deterrent formulations (ADF) in opioids in terms of overall cost vs. abuse-deterrent capability that they provide. We at Prime Therapeutics (Prime) believe opioids play an important role in pain management; however, we remain concerned about overprescribing of ADF opioids, especially when they can still be used in excess quantities and for illegitimate means. The fact is these products have not shown that they materially improve outcomes. If laws mandate ADFs over traditional opioids it will add billions of dollars to the U.S. health care system with limited benefits, and may even lead to unintended negative consequences of alternative narcotic abuse. While Prime supports ADF technology, these formulations alone are not going to solve the epidemic, and thus shouldn't consume a disproportionate amount of the dollars to address the epidemic, which will happen if their use is mandated. With so many lives at stake, policy makers and the healthcare industry need to stay focused on backing comprehensive, evidence-based solutions."

The voting body at the public meeting concluded:

  • there was not enough evidence to demonstrate a reduced risk of abuse for people using immediate-release ADF RoxyBondTM over a non-ADF immediate release opioid.  
  • there was enough evidence of reduced risk of abuse to support using the extended-release ADF OxyContin® over its non-ADF opioid counterparts, but there was not enough evidence to support using other extended release ADF opioids.  
  • there was not enough evidence to demonstrate a net health benefit on a population level with the use of Oxycontin® vs. non-ADF extended release opioids.  
  • that the most appropriate public policy to pursue is to develop a way for physicians to work for payers, policy makers and addiction treatment centers to target ADFs to the highest risk people to help guide the prescriber in their decision making.
  • For details on the questions and results visit @icer_review on Twitter.

    About Prime Therapeutics
    Prime Therapeutics LLC (Prime) helps people get the medicine they need to feel better and live well. Prime manages pharmacy benefits for health plans, employers, and government programs including Medicare and Medicaid. The company processes claims and delivers medicine to members, offering clinical services for people with complex medical conditions. Prime serves more than 20 million people. It is collectively owned by 14 Blue Cross and Blue Shield Plans, subsidiaries or affiliates of those plans.


    Contact:

    Karen Lyons, APRPrime TherapeuticsDirector, Corporate Communications612.777.5742KLyons@primetherapeutics.com

     

    View original content:http://www.prnewswire.com/news-releases/prime-therapeutics-urges-caution-on-mandates-of-abuse-deterrent-formulations-of-opioids-citing-value-concerns-300491983.html


    '/>"/>
    SOURCE Prime Therapeutics LLC
    Copyright©2017 PR Newswire.
    All rights reserved


    Related medicine technology :

    1. Research Reports Initiation on Biotech Stocks -- Epizyme, Sierra Oncology, Five Prime Therapeutics, and AveXis
    2. Paramed: Primer escáner MRI abierto en Gales y el séptimo sistema en el Reino Unido
    3. BioMarin Receives Access to Priority Medicines (PRIME) Regulatory Support from EMA for BMN 270 Gene Therapy in Hemophilia A
    4. Prime Therapeutics is Certified for NCQA Utilization Management and Health Information Products - Pharmacy Benefit Information
    5. Takara Bio USA, Inc. and TeselaGen Biotechnology, Inc. Release a Powerful New Primer Tool for Easy Design of In-Fusion Cloning Experiments
    6. 22 compañías biofarmacéuticas lanzan la primera iniciativa para abordar las enfermedades no comunicables
    7. Prime Therapeutics fills new chief of sales position
    8. Two Prime Therapeutics pharmacists achieve awards from Academy of Managed Care Pharmacy
    9. Prime Therapeutics Research Finds Increase in Insulin Use, Pharmacy Expense
    10. Prime Therapeutics Releases Studies on Efforts to Reduce Opioid Abuse, Misuse
    11. Prime Therapeutics Statement on U.S. Food and Drug Administrations Approval of Biosimilar Inflectra
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:10/12/2017)... , Oct. 12, 2017 West ... in innovative solutions for injectable drug administration, today announced ... the market opens on Thursday, October 26, 2017, and ... results and business expectations at 9:00 a.m. Eastern Time. ... or 253-336-8738 (International). The conference ID is 94093362. ...
    (Date:10/10/2017)... Calif. , Oct. 10, 2017  NDS received FDA 510(k) ... — a medical-grade battery-powered display stand specifically designed for endoscopy environments. ... transform technology into a clinical solution to support the improvement of ... Innovative Design ... Mobile Wireless Solution ...
    (Date:10/4/2017)... 2017  According to the Centers for Disease Control and Prevention (CDC), ... PhysicianOne Urgent Care is helping communities across Massachusetts , ... by offering no-cost* flu shots through the end of the month. ... insurance regulations. ... get a flu shot is by the end of October, according to ...
    Breaking Medicine Technology:
    (Date:10/13/2017)... LEXINGTON, Ky. (PRWEB) , ... October 13, 2017 , ... ... MD, MPH to become its next President and Chief Executive Officer, succeeding Dr. James ... and CEO Elect beginning July 1, 2018 until Dr. Puffer’s retirement at the end ...
    (Date:10/13/2017)... CT (PRWEB) , ... October 13, 2017 , ... ... long-term care services, staged a mock evacuation of the facility as part of a ... Shelton Fire Department, Echo Hose EMS and Shelton City Emergency Manager, as well as ...
    (Date:10/13/2017)... ... ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh, has released ... understood books in the Holy Scriptures, Revelation. The Book of Revelation paints a picture ... Many have tossed it off as mere rubbish, but Yisrayl Hawkins says that is ...
    (Date:10/12/2017)... ... October 12, 2017 , ... First ... compliance program management, will showcase a range of technology and learning solutions at ... (NCAL) Convention and Expo to be held October 14–18, 2017 at the Mandalay ...
    (Date:10/12/2017)... ... October 12, 2017 , ... The American College of Medical Informatics ... PhD, FACMI, during the Opening Session of AMIA’s Annual Symposium in Washington, D.C. AMIA’s ... of Morris F. Collen, a pioneer in the field of medical informatics, this prestigious ...
    Breaking Medicine News(10 mins):